1 / 28

Frozen Section of Sentinel lymph node for Ductal Carcinoma in Situ (DCIS)

Frozen Section of Sentinel lymph node for Ductal Carcinoma in Situ (DCIS). Dr Cheung Chi Ying Genevieve. Cox CE, Ann Surg. 1998. Introduction. SLNBx is well recognized in invasive breast cancer avoid full axillary dissection decrease the morbidity associated with axillary dissection

fuller-knight
Télécharger la présentation

Frozen Section of Sentinel lymph node for Ductal Carcinoma in Situ (DCIS)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frozen Section ofSentinel lymph node forDuctal Carcinoma in Situ (DCIS) Dr Cheung Chi Ying Genevieve

  2. Cox CE, Ann Surg. 1998 Introduction • SLNBx is well recognized in invasive breast cancer • avoid full axillary dissection • decrease the morbidity associated with axillary dissection • Surgical techniques were well described and were mastered by many surgeons

  3. SLNBx in DCIS • Increasing interest of SLNBx in other applications in breast surgery • DCIS • DCIS is the precursor of invasive cancer

  4. Incidence of DCIS is increasing in the screening era • From 3/100000 to 34/100000 in 50-69 y.o. • Prognosis of pure DCIS is excellent • 5 years survival >95% Van Steenbergen LN et al, breast cancer rest treat. 2009

  5. Controversial issues Pre op trucut biopsy of DCIS not 100% ! About 29.9% of these group had upstaging of disease in final pathology WK Hung et al, Breast cancer 2009

  6. Controversial issues Pure DCIS theoretically will not have any LN metastasis Management of axilla SLNBx for F.S.? Axillary dissection or not? If not -> miss the invasive disease that need AD? Veronesi P et al, Breast. 2005

  7. Current recommendation • Selective application in high risk DCIS • Extensive microcalcifications • Palpable mass • High nuclear grade • Requiring mastectomy • SLNBx is not possible as a 2nd procedure Schneider C et al, Am Surg. 2010 D’Eredita G et al, Tumori. 2009

  8. KWH experience inSLNBx for DCIS • In KWH, SLNBx technique was introduced for DCIS since year 2002 • Results of KWH experience of SLNBx in DCIS are being presented here

  9. Patients • Retrospective study • Period: 3/2002 till 6/2010 • Total number of patients: 170 • Inclusion • Preop trucut Biopsy: DCIS

  10. Patients • Exclusion • Patient with microinvasive disease on trucut bx • Patients with DCIS diagnosed after OT • Mean age: 54.4 years old

  11. Presentation

  12. Operation

  13. Methods of mapping • Methods used for localization of SLN • Blue dye method • Intra-op sub-dermal injection of Patent Blue • Isotope method • Pre-op scintigraphy with 99m Tc Sulfur colloid • Localization with intra-op hand-held gamma probe • Combined

  14. Frozen section The sentinel LN would be sent to the laboratory immediately The pathologist would then give a verbal report Whether the LN is positive for any macrometastasis

  15. Results • SLNBx was successful in 162 (95%) of patients • 5 patients (3%) had +ve SLN on frozen section intraoperatively • Axillary dissection was carried out

  16. Results • 12 patients (7%) had false –ve FS • Axillary dissection was carried out in 6 of them

  17. Pre-op core biopsy : DCIS170 SLN Failed8 (5%) SLN Successful162 (95%) F.S. +ve5 (3%) F.S. –ve157 (92%) False –ve12 (7%) True –ve145 (85%) 3 A.D. –ve(2%)2 A.D. +ve(1%) A.D. 6(3.5%) No A.D.6 (3.5%)

  18. Pre-op core biopsy : DCIS170 SLN Failed8 (5%) SLN Successful162 (95%) F.S. +ve5 (3%) F.S. –ve157 (92%) False –ve12 (7%) True –ve145 (85%) 3 A.D. –ve(2%)2 A.D. +ve(1%) A.D. 6(3.5%) No A.D.6 (3.5%)

  19. Discussion • 11 axillary dissections were done • Only 3 of them were +ve in AD • Final pathology • invasive ductal carcinoma

  20. Summary

  21. SLN Successful162 (95%) SLN for P.S. Positive17 (10%) Negative145 (85%) No A.D.6 (4%) A.D. 11 (6%) DCIS3 (2%) Invasive ductal CA8 (5%) All AD -ve AD –ve 5 (3%)AD +ve 3 (2%)

  22. SLN Successful162 (95%) SLN for P.S. Positive17 (10%) Negative145 (85%) No A.D.6 (4%) A.D. 11 (6%) DCIS3 (2%) Invasive ductal CA8 (5%) All AD -ve AD –ve 5 (3%)AD +ve 3 (2%)

  23. SLN Successful162 (95%) SLN for P.S. Positive17 (10%) Negative145 (85%) No A.D.6 (4%) A.D. 11 (6%) DCIS3 (2%) Invasive ductal CA8 (5%) All AD -ve AD –ve 5 (3%)AD +ve 3 (2%)

  24. For pure DCIS with +ve sentinel lymph node either in F.S. or paraffin section SLN is the only LN that is +ve rest of axilla is -ve Discussion

  25. Axillary dissection and intraop frozen section for pure DCIS is unnecessary Discussion

  26. For pure DCIS, taking out the SLN would be enough without the need of further axillary dissection Discussion

  27. Hypothetically, if no F.S. was done for DCIS Potentially save 162 frozen sections 3 axillary dissections Discussion

  28. Thank you

More Related